RxDoctor Payments Data

Kathleen Feighery, APRN

Family · Ft Wright, KYNPI 1477191823

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 56 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$747
  • AstraZeneca$68
  • Lilly USA, LLC$41
  • Exact Sciences$33
  • Inspire Medical Systems, Inc.$25
  • Astellas Pharma US Inc$22
  • plus $88 from 6 others

What the payments were for

  • Food & beverage$1,024100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,024 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$18,295
Medicare patients
117
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$22,084
Nurtec OdtRimegepant Sulfate12$18,182
VraylarCariprazine Hcl12$16,726
FarxigaDapagliflozin Propanediol14$16,317
SymbicortBudesonide/Formoterol Fumarate11$2,553
Omeprazole107$1,670
Ventolin HfaAlbuterol Sulfate23$1,284
Fenofibrate12$1,136
Levothyroxine Sodium121$1,040
Celecoxib19$854
Gabapentin88$791
Albuterol Sulfate HfaAlbuterol Sulfate35$789
Pravastatin Sodium66$760
Bupropion XlBupropion Hcl24$728
Hydroxyzine Hcl42$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$22,08420 claims
AstraZenecaFarxiga, Symbicort$68$18,87025 claims
AbbVieVraylar, Armour Thyroid$747$17,23523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Ft Wright

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →